Industry Briefs: July 9, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
AstraZeneca has completed the previously announced sale of the assets of its subsidiary, Aptium Oncology.
Cancer Research Technology (CRT), the commercial arm of Cancer Research UK, and ADC Therapeutics Sarl (ADCT) have signed agreements to develop antibody drug conjugates using CRT’s antibodies and peptides, and ADCT’s linker chemistries and proprietary pyrrolobenzodiazepines technology.
The CureBeta R&D collaboration between Evotec and Harvard University has entered into a strategic alliance with Janssen Pharmaceuticals.
Hal Allergy has expanded its GMP contract manufacturing activities for clinical-batch supply of both recombinant and viral products.
Prokarium, a spin-out company of Cobra Biologics, has acquired oral-vaccine technology from Emergent BioSolutions.
Sanofi has agreed to divest its 19.3% stake in the Yves Rocher Group.
Spectrum Pharmaceuticals has provided an additional extension of the offer period in connection with its tender offer to purchase all of the outstanding shares of common stock of Allos Therapeutics for $1.82 per share in cash.
People News
Affymax has named Michael Holfinger vice-president of manufacturing and CMC development.
Arena Pharmaceuticals has appointed Craig M. Audet to executive officer as senior vice-president, operations, and head of global regulatory affairs.
Chiral Technologies has appointed Jauh-Tzuoh Lee as technology manager.
Ricerca Biosciences named G. Lynn Miesel technical director.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.